The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Correlative biomarker analysis of sequential tumor biopsies in a ph I mode of action (MoA) study in neoadjuvant head and neck squamous cell carcinoma (HNSCC) patients (pts) treated with RG7160 (GA201), a novel dual-acting, monoclonal antibody (mAb) designed to enhance antibody-dependent cellular cytotoxicity (ADCC), with cetuximab (C) as reference.
Christoph Mancao
Employment or Leadership Position - Roche
Stock Ownership - Roche
Lilla Di Scala
Employment or Leadership Position - Roche
Stock Ownership - Roche
Paul Delmar
Employment or Leadership Position - Roche
Stéphane Temam
Honoraria - Roche
Jean-Charles Soria
Consultant or Advisory Role - Roche
Honoraria - Roche
James F. Spicer
Research Funding - Guys Hospital
Mark McGurk
No relevant relationships to disclose
Jean-Pierre Delord
No relevant relationships to disclose
Jerome Sarini
No relevant relationships to disclose
Niels Halama
Research Funding - Roche
Stefan Evers
Employment or Leadership Position - Roche
Stock Ownership - Roche
Alexandre Passioukov
Employment or Leadership Position - Roche